Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | PGR | P06401 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4758577 | 0.88 | TSHR (0.36) | TSHRLMNAL3MBTL1NOTUMCYP2C9 | |
| SCHEMBL7289569 | 0.76 | BACE1 (0.36) | DRD2ADRA1A | |
| SCHEMBL4758583 | 0.74 | PYGL (0.38) | TSHRLMNAL3MBTL1NOTUMCYP2C9 | |
| SCHEMBL2365028 | 0.74 | TSHR (0.37) | TSHRLMNAL3MBTL1NOTUMCYP2C9 | |
| SCHEMBL4758043 | 0.73 | CRHBP (0.40) | LMNAL3MBTL1NOTUMCYP2C9KMT2A | |
| SCHEMBL8672508 | 0.70 | GPBAR1 (0.37) | LMNAKMT2AALDH1A1DRD2KDM4E | |
| SCHEMBL4757311 | 0.68 | TSHR (0.37) | TSHRLMNANOTUMCYP2C9KMT2A | |
| SCHEMBL7267168 | 0.68 | NOTUM (0.44) | TSHRLMNANOTUMALDH1A1DRD2 | |
| SCHEMBL7424308 | 0.68 | ALDH1A1 (0.38) | TSHRLMNAL3MBTL1NOTUMCYP2C9 | |
| SCHEMBL4883866 | 0.68 | TP53 (0.43) | TSHRLMNAL3MBTL1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282783-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS | Stablix, Inc. | 2025-09-11 | — | — | US | disclosed |
| US-20240358842-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP7 LIGANDS | Stablix, Inc. | 2024-10-31 | — | — | US | disclosed |
| WO-2022272133-A2 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP7 LIGANDS | Stablix, Inc. (US) | 2022-12-29 | — | — | WO | disclosed |
| CN-113388007-A | Ultra-pure agonists of guanylate cyclase C, methods of making and using the same | 博士医疗爱尔兰有限公司 | 2021-09-14 | — | — | CN | disclosed |
| CN-105764916-B | Ultra-pure agonists of guanylate cyclase C, methods of making and using the same | 博士医疗爱尔兰有限公司 | 2021-05-18 | — | — | CN | disclosed |
| CN-102858361-B | Agonists of guanylate cyclase for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstones, obesity and other cardiovascular diseases | 药物协和股份有限公司 | 2016-08-03 | — | — | CN | disclosed |
| US-5519012-A | CALCIUM ANTAGONISTS, CARDIOVASCULAR DISORDERS | LEK, TOVARNA FARMACEVTSKIH IN KEMICNIH IZDELKOV, D.D., LJUBLJANA (SI) | 1996-05-21 | — | — | US | disclosed |
| EP-0566142-A1 | Inclusion complexes of optically active and racemic 1,4-dihydro pyridines with cyclodextrin derivates | LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. (SI) | 1993-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282783-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS | USP28, USP25, USP24 | TSHR 2771/4885LMNA 3720/4885L3MBTL1 1158/4885 |
| US-20240358842-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP7 LIGANDS | USP7, UBQLN1, UBQLN2 | TSHR 3439/4885LMNA 3276/4885L3MBTL1 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.